Claims
- 1. A monoclonal antibody specific for a glycoprotein which is a marker for human squamous lung carcinoma, where the marker is a carbohydrate sequence found on a plurality of glycoproteins in excess of about 50kDal and substantially absent in (1) carcinomas of organs other than lung, (2) leukemias and (3) sarcomas; and wherein said monoclonal antibody specific for a glycoprotein binds to the saccharide portion of said glycoprotein which is recognized specifically by IgM monoclonal antibody designated 43-9F secreted by hybridoma cell line having deposit no. ECACC 85013101.
- 2. A monoclonal antibody according to claim 1, wherein said monoclonal antibody is a human monoclonal antibody.
- 3. A monoclonal antibody according to claim 1 of the isotype IgM.
- 4. A monoclonal antibody according to claim 1, wherein said monoclonal antibody is a mouse monoclonal antibody.
- 5. A monoclonal antibody according to claim 4 of the isotype IgM.
- 6. A fragment of a monoclonal antibody according to claim 1, including at least the F.sub.v portion.
- 7. A monoclonal antibody specific for the idiotype of a glycoprotein binding monoclonal antibody according to claim 1.
- 8. A monoclonal antibody according to claim 7, wherein said glycoprotein binding monoclonal antibody is a human monoclonal antibody.
- 9. An IgM monoclonal antibody designated 43-9F secreted by a hybridoma cell line having deposit no. ECACC 85013101.
- 10. An isolated, purified polysaccharide characterized as being present in glycoproteins released by human squamous lung cancer cells, said glycoproteins being of less than about 250kDal, and binding specifically to a monoclonal antibody according to claim 9.
- 11. An isolated, purified polysaccharide according to claim 10, of less than about 45kDal.
- 12. An isolated, purified glycoprotein composition comprising glycoproteins of from about 50kDal to about 1mDal capable of binding to a monoclonal antibody according to claim 9, derived from human squamous lung cancer cells and substantially free of other human squamous lung cancer cell glycoproteins and proteins.
- 13. A glycoprotein composition according to claim 12, purified by chromatography on a gel permeation column and eluting with phosphate buffered saline containing a small amount of a non-ionic detergent.
- 14. A monoclonal antibody prepared in immunogenic response to a glycoprotein composition according to claim 12.
- 15. An immortalized B-lymphocytic cell line secreting a monoclonal antibody according to claim 1.
- 16. An immortalized B-lymphocytic cell line according to claim 15, wherein said cell line is a human cell line.
- 17. An immortalized B-lymphocytic cell line according to claim 15, wherein said cell line is a mouse cell line.
- 18. An immortalized B-lymphocytic cell line according to claim 17, wherein said cell line is hybridoma cell line designated 43- 9F having deposit no. ECACC 85013101.
- 19. An immortalized B-lymphocytic cell line secreting a monoclonal antibody according to claim 7.
- 20. A method for detecting the presence of squamous lung cancer in a human host, which comprises:
- combining a sample from said human host suspected of having a polysaccharide according to claim 10 or endogenous antibodies to said polysaccharide with monoclonal antibodies specific for said polysaccharide or the idiotype of said endogenous antibodies; and
- detecting the formation of immune complexes as indicative of the presence or prior presence of squamous lung cancer cells.
- 21. A method according to claim 20, wherein said sample is blood or serum.
- 22. A method according to claim 20, wherein said method is the dot-blot method.
- 23. A method according to claim 20, wherein said monoclonal antibody or a second antibody to said monoclonal antibody is conjugated to a label capable of providing a detectable signal.
- 24. A method according to claim 23, wherein said label is a radionuclide, fluorescer or enzyme.
- 25. A kit for use in a method for detecting the presence of squamous lung cancer in a human host comprising a monoclonal antibody according to claim 1 or 7, wherein said monoclonal antibody is conjugated to a label capable of providing a detectable signal or a second antibody to one of said monoclonal antibodies is includes, wherein said second antibody is conjugated to a label capable of providing a detectable signal, and a composition including a polysaccharide specifically binding to IgM monoclonal antibody designated 43-9F secreted by hybridoma cell line having deposit no. ECACC 85013101.
- 26. A monoclonal antibody according to claim 1 conjugated directly or indirectly to a label capable of providing a detectable signal.
- 27. A monoclonal antibody according to claim 26, wherein said label is a radionuclide, fluorescer or enzyme.
Parent Case Info
This is a continuation of application Ser. No. 701,322, filed Feb. 13, 1985, now abandoned.
Non-Patent Literature Citations (1)
Entry |
Martensson, S., et al., Cancer Res., 48:2125-2131, (1988). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
701322 |
Feb 1985 |
|